Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0086 Transporter Info
Gene Name SLC12A5
Transporter Name Electroneutral potassium-chloride cotransporter 2
Gene ID
57468
UniProt ID
Q9H2X9
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Ivermectin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ivermectin inhibits the expression of SLC12A5 [1]

  Furosemide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Furosemide inhibits the activity of SLC12A5 [2] , [3]

  Reserpine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Reserpine inhibits the activity of SLC12A5 [4]

Drug in Phase 2 Trial

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A inhibits the expression of SLC12A5 [6]

Drug in Preclinical Test

  AM-2282

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 AM-2282 increases the activity of SLC12A5 [5]

Investigative Drug

  N-ethylmaleimide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 N-ethylmaleimide increases the activity of SLC12A5 [5]

Health and Environmental Toxicant

  Butyraldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Butyraldehyde inhibits the expression of SLC12A5 [7]

  Lead

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lead affects the expression of SLC12A5 [8]
References
1 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975.
2 Downregulation of KCC2 following LTP contributes to EPSP-spike potentiation in rat hippocampus. Biochem Biophys Res Commun. 2006 May 19;343(4):1209-15.
3 Chloride homeostasis differentially affects GABA(A) receptor- and glycine receptor-mediated effects on spontaneous circuit activity in hippocampal cell culture. Neurosci Lett. 2006 Oct 2;406(1-2):11-6.
4 Blockade of spinal 5-GABAa receptors differentially reduces reserpine-induced fibromyalgia-type pain in female rats. Eur J Pharmacol. 2019 Jun 7:172443.
5 A thallium transport FLIPR-based assay for the identification of KCC2-positive modulators. J Biomol Screen. 2010 Feb;15(2):177-84.
6 Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter. Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4315-20.
7 Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology. 2015 Aug 6;334:111-21.
8 RNA-Seq of Human Neural Progenitor Cells Exposed to Lead (Pb) Reveals Transcriptome Dynamics, Splicing Alterations and Disease Risk Associations. Toxicol Sci. 2017 Sep 1;159(1):251-265.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.